

Siegfried Success Story : Arena Pharmaceuticals

Siegfried is Arena's preferred partner

Siegfried is a preferred development partner of Arena Pharmaceuticals, a San Diego-based, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs. Their lead compound, locaserin, is an anti-obesity drug which is currently in phase III clinical trials. Siegfried has sold Arena its pharmaceutical dosage manufacturing facility in Zofingen, Switzerland, in early 2008.

By making our full in-house operation capabilities available to Arena, we help them drive down their development and manufacturing costs while significantly increasing the volume of business. Arena's focus is on innovative research. Siegfried's focus is operational excellence. By plugging into our capabilities they get the benefit of being a fully-integrated pharmaceutical company without getting distracted from their primary mission, which is to discover innovative drugs.

To quote the January 14th, 2008 Pharma Marketletter: „The U.S. firm believes that the deal has the potential to: reduce manufacturing-related risks to the locaserin NDA registration lots and submission of ist planned filing; secure a long-term supply of active pharmaceutical ingredients; reduce the overall manufacturing costs for this agent and other Arena product candidates; and lead to significant future tax benefits.“